Last updated on March 2020

A Study of Nivolumab Plus NKTR-214 vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin a Type of Medicine Given to Treat Bladder Cancer.


Brief description of study

The purpose of the study is to see if treatment with nivolumab plus NKTR-214 or nivolumab alone, before and after surgery to remove the bladder, is more effective than surgery alone in participants with muscle-invasive bladder cancer who are not able to receive cisplatin chemotherapy.

Clinical Study Identifier: NCT04209114

Find a site near you

Start Over

Local Institution

Marseille Cedex 9, France
  Connect »